The Angiopoietin-Tie2 pathway is a potential therapeutic target in urothelial carcinoma

Anticancer Research

Volumn 34, Issue 7, 2014, Pages 3377-3382

  Jian, Weiguo ^a   Levitt, Jonathan M ^a   Lerner, Seth P ^a   Sonpavde, Guru ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b and Clinical Center   (United States)

Author keywords

Angiopoietin TIE2; CEP11981; FGFR; Tyrosine kinase inhibitor; Urothelial carcinoma; VEGFR

Indexed keywords

ANGIOPOIETIN RECEPTOR; ANTINEOPLASTIC AGENT; CASPASE 3; CD31 ANTIGEN; CEP 11981; FIBROBLAST GROWTH FACTOR RECEPTOR 1; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 3; 11-(2-METHYLPROPYL)-12,13-DIHYDRO-2-METHYL-8-(PYRIMIDIN-2-YLAMINO)-4H-INDAZOLO(5,4-A)PYRROLO(3,4-C)CARBAZOL-4-ONE; 11 (2 METHYLPROPYL) 12,13 DIHYDRO 2 METHYL 8 (PYRIMIDIN 2 YLAMINO) 4H INDAZOLO(5,4 A)PYRROLO(3,4 C)CARBAZOL 4 ONE; ANGIOPOIETIN; CARBAZOLE DERIVATIVE; INDAZOLE DERIVATIVE;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL LINE; CONTROLLED STUDY; DIFFERENTIATION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TRANSITIONAL CELL CARCINOMA; TUMOR RECURRENCE; TUMOR XENOGRAFT; ANGIOPOIETIN/TIE2; ANIMAL; CEP11981; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; ENZYMOLOGY; FEMALE; FGFR; METABOLISM; NUDE MOUSE; RANDOMIZATION; TUMOR CELL LINE; URINARY TRACT CANCER; VEGFR;

ANGIOPOIETIN/TIE2; CEP11981; FGFR; TYROSINE KINASE INHIBITOR; UROTHELIAL CARCINOMA; VEGFR;

ANGIOPOIETINS; ANIMALS; CARBAZOLES; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INDAZOLES; MICE; MICE, NUDE; RANDOM ALLOCATION; RECEPTOR, TIE-2; SIGNAL TRANSDUCTION; UROLOGIC NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84906309011     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Logothetis CJ, Dexeus FH, Finn L, Sella A, Amato RJ, Ayala AG and Kilbourn RG: A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 8: 1050-1055, 1990.
2. von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ, Bodrogi I, Albers P, Knuth A, Lippert CM, Kerbrat P, Sanchez Rovira P, Wersall P, Cleall SP, Roychowdhury DF, Tomlin I, Visseren-Grul CM and Conte PF: Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 18: 3068-3077, 2000.
3. Saxman SB, Propert KJ, Einhorn LH, Crawford ED, Tannock I, Raghavan D, Loehrer PJ Sr. and Trump D: Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 15: 2564-2569, 1997.
4. Loehrer PJ, Sr., Einhorn LH, Elson PJ, Crawford ED, Kuebler P, Tannock I, Raghavan D, Stuart-Harris R, Sarosdy MF, Lowe BA et al: A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 10: 1066-1073, 1992.
5. Sternberg CN, de Mulder P, Schornagel JH, Theodore C, Fossa SD, van Oosterom AT, Witjes JA, Spina M, van Groeningen CJ, Duclos B, Roberts JT, de Balincourt C and Collette L: Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. European Journal of Cancer 42: 50-54, 2006.
6. Galsky MD, Chen GJ, Oh WK, Bellmunt J, Roth BJ, Petrioli R, Dogliotti L, Dreicer R and Sonpavde G: Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma. Annals of oncology: official journal of the European Society for Medical Oncology/ESMO. 2011 May 4:
7. von der Maase H, Sengelov L, Roberts JT, Ricci S, Dogliotti L, Oliver T, Moore MJ, Zimmermann A and Arning M: Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 23: 4602-4608, 2005.
8. Dreicer R, Li H, Stein M, DiPaola R, Eleff M, Roth BJ and Wilding G: Phase 2 trial of sorafenib in patients with advanced urothelial cancer: a trial of the Eastern Cooperative Oncology Group. Cancer 115: 4090-4095, 2009.
9. Dreicer R, Gustin DM, See WA and Williams RD: Paclitaxel in advanced urothelial carcinoma: its role in patients with renal insufficiency and as salvage therapy. The Journal of urology 156: 1606-1608, 1996.
10. Dreicer R, Li S, Manola J, Haas NB, Roth BJ, Wilding G, Eastern Cooperative Oncology G: Phase 2 trial of epothilone B analog BMS-247550 (ixabepilone) in advanced carcinoma of the urothelium (E3800): a trial of the Eastern Cooperative Oncology Group. Cancer 15: 110: 759-763, 2007.
11. Sweeney CJ, Roth BJ, Kabbinavar FF, Vaughn DJ, Arning M, Curiel RE, Obasaju CK, Wang Y, Nicol SJ and Kaufman DS: Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 24: 3451-3457, 2006.
12. Witte RS, Elson P, Bono B, Knop R, Richardson RR, Dreicer R and Loehrer PJ Sr: Eastern Cooperative Oncology Group phase II trial of ifosfamide in the treatment of previously treated advanced urothelial carcinoma. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 15: 589-593, 1997.
13. Wulfing C, Machiels JP, Richel DJ, Grimm MO, Treiber U, De Groot MR, Beuzeboc P, Parikh R, Petavy F and El-Hariry IA: A single-arm, multicenter, open-label phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma. Cancer 115: 2881-2890, 2009.
14. McCaffrey JA, Hilton S, Mazumdar M, Sadan S, Kelly WK, Scher HI and Bajorin DF: Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 15: 1853-1857, 1997.
15. Albers P, Siener R, Hartlein M, Fallahi M, Haeutle D, Perabo FG, Steiner G, Blatter J and Muller SC: Gemcitabine monotherapy as second-line treatment in cisplatin-refractory transitional cell carcinoma - prognostic factors for response and improvement of quality of life. Onkologie 25: 47-52, 2002.
16. Lorusso V, Pollera CF, Antimi M, Luporini G, Gridelli C, Frassineti GL, Oliva C, Pacini M and De Lena M: A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Cooperative Group on Bladder Cancer. European journal of cancer 34: 1208-1212, 1998.
17. Vaughn DJ, Broome CM, Hussain M, Gutheil JC and Markowitz AB: Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 20: 937-940, 2002.
18. Bellmunt J, Theodore C, Demkov T, Komyakov B, Sengelov L, Daugaard G, Caty A, Carles J, Jagiello-Gruszfeld A, Karyakin O, Delgado FM, Hurteloup P, Morsli N, Salhi Y, Culine S and von der Maase H: Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 17: 2009.
19. Sonpavde G, Sternberg CN, Rosenberg JE, Hahn NM, Galsky MD and Vogelzang NJ: Second-line systemic therapy and emerging drugs for metastatic transitional-cell carcinoma of the urothelium. The lancet oncology 11: 861-870, 2010.
20. Yang CC, Chu KC and Yeh WM: The expression of vascular endothelial growth factor in transitional cell carcinoma of urinary bladder is correlated with cancer progression. Urol Oncol 22: 1-6, 2004.
21. Kong C, Zhu Y, Sun C, Li Z, Sun Z, Zhang X and Takanaka I: Inhibition of tumor angiogenesis during cisplatin chemotherapy for bladder cancer improves treatment outcome. Urology 65: 395-399, 2005.
22. Sonpavde G, Jian W, Liu H, Wu MF, Shen SS and Lerner SP: Sunitinib malate is active against human urothelial carcinoma and enhances the activity of cisplatin in a preclinical model. Urol Oncol 27: 391-399, 2009.
23. Xia G, Kumar SR, Hawes D, Cai J, Hassanieh L, Groshen S, Zhu S, Masood R, Quinn DI, Broek D, Stein JP and Gill PS: Expression and significance of vascular endothelial growth factor receptor 2 in bladder cancer. The Journal of urology 175: 1245-1252, 2006.
24. Hahn NM, Stadler WM, Zon RT, Waterhouse D, Picus J, Nattam S, Johnson CS, Perkins SM, Waddell MJ and Sweeney CJ: Phase II trial of cisplatin, gemcitabine, and bevacizumab as first-line therapy for metastatic urothelial carcinoma: Hoosier Oncology Group GU 04-75. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 29: 1525-1530, 2011.
25. Balar AV, Apolo AB, Ostrovnaya I, Mironov S, Iasonos A, Trout A, Regazzi AM, Garcia-Grossman IR, Gallagher DJ, Milowsky MI and Bajorin DF: Phase II study of gemcitabine, carboplatin, and bevacizumab in patients with advanced unresectable or metastatic urothelial cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 31: 724-730, 2013.
26. Bellmunt J, Gonzalez-Larriba JL, Prior C, Maroto P, Carles J, Castellano D, Mellado B, Gallardo E, Perez-Gracia JL, Aguilar G, Villanueva X, Albanell J and Calvo A: Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity. Annals of oncology: official journal of the European Society for Medical Oncology/ESMO 22: 2646-2653, 2011.
27. Gallagher DJ, Milowsky MI, Gerst SR, Ishill N, Riches J, Regazzi A, Boyle MG, Trout A, Flaherty AM and Bajorin DF: Phase II study of sunitinib in patients with metastatic urothelial cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 28: 1373-1379, 2010.
28. Maisonpierre PC, Suri C, Jones PF, Bartunkova S, Wiegand SJ, Radziejewski C, Compton D, McClain J, Aldrich TH, Papadopoulos N, Daly TJ, Davis S, Sato TN and Yancopoulos GD: Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 277: 55-60, 1997.
29. Yuan HT, Khankin EV, Karumanchi SA and Parikh SM: Angiopoietin 2 is a partial agonist/antagonist of Tie2 signaling in the endothelium. Molecular and cellular biology 29: 2011-2022, 2009.
30. Mita AC, Takimoto CH, Mita M, Tolcher A, Sankhala K, Sarantopoulos J, Valdivieso M, Wood L, Rasmussen E, Sun YN, Zhong ZD, Bass MB, Le N and LoRusso P: Phase 1 study of AMG 386, a selective angiopoietin 1/2-neutralizing peptibody, in combination with chemotherapy in adults with advanced solid tumors. Clin Cancer Res 16: 3044-56, 2010.
31. Eroglu Z, Stein CA and Pal SK: Targeting angiopoietin-2 signaling in cancer therapy. Expert opinion on investigational drugs 22: 813-825, 2013.
32. Hudkins RL, Becknell NC, Zulli AL, Underiner TL, Angeles TS, Aimone LD, Albom MS, Chang H, Miknyoczki SJ, Hunter K, Jones-Bolin S, Zhao H, Bacon ER, Mallamo JP, Ator MA and Ruggeri BA: Synthesis and biological profile of the pan-vascular endothelial growth factor receptor/tyrosine kinase with immunoglobulin and epidermal growth factor-like homology domains 2 (VEGF-R/TIE-2) inhibitor 11-(2-methylpropyl)-12,13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4H-indazolo[5, 4-a]pyrrolo[3,4-c]carbazol-4-one (CEP-11981): a novel oncology therapeutic agent. Journal of medicinal chemistry 55: 903-913, 2012.
33. Ruggeri B, Underiner T, Gingrich D et al: CEP-11981: A potent TIE-2/Pan-VEGF-R inhibitor with broad kinase inhibitory activity exhibits significant antitumor and antiangiogenic efficacy in preclinical tumor models. AACR Meeting Abstracts 2007: B264, 2007.
34. Oka N, Yamamoto Y, Takahashi M, Nishitani M, Kanayama HO and Kagawa S: Expression of angiopoietin-1 and -2, and its clinical significance in human bladder cancer. BJU Int 95: 660-663, 2005.
35. Szarvas T, Jager T, Totsch M, vom Dorp F, Kempkensteffen C, Kovalszky I, Romics I, Ergun S and Rubben H: Angiogenic switch of angiopietins-Tie2 system and its prognostic value in bladder cancer. Clin Cancer Res 14: 8253-8262, 2008.
36. Quentin T, Schlott T, Korabiowska M, Kathei N, Zoller G, Glaser F and Kunze E: Alteration of the vascular endothelial growth factor and angiopoietins-1 and -2 pathways in transitional cell carcinomas of the urinary bladder associated with tumor progression. Anticancer Res 24: 2745-2756, 2004.